Trial · NCT05696613
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
NCT05696613, Phase 3, Recruiting, Cerium Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy. Trials, record NCT05696613. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05696613
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
- NCT number
- NCT05696613
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 148 participants, estimated
- Lead sponsor
- Cerium Pharmaceuticals, Inc.
- Conditions
- Primary Membranous Nephropathy
- Interventions
- SNP-ACTH (1-39) Gel, Rituximab
- First posted
- 2023-01-25
- Last updated
- 2026-06-25
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in urinary protein (Phase 3a) | Change from baseline, months 1, 2, 3, 4, 5, 6, 9, and 12 | |
| Primary | Change in Anti-phospholipase A2 receptor (PLA2R) auto-antibody levels (Phase 3a) | Change from baseline, months 1, 2, 3, 4, 6, and 12 | |
| Primary | Complete response of PMN (Phase 3b) | 24 months | Reduction of proteinuria to ≤0.3 g/24 hours as measured by urine protein/creatinine ratio obtained from a 24-hour urine collection with stable renal function defined as a \<15% decline in eGFR at the time of endpoint assessment |
| Secondary | Relapse rate at month 12 and month 24. | 12 and 24 months | |
| Secondary | Anti-PLA2R (or Anti-THSD7A) auto-antibody levels. | 12 and 24 months | |
| Secondary | Estimated glomerular filtration rate (eGFR) with proteinuria levels. | 12 and 24 months | |
| Secondary | Adverse events | 24 months | |
| Secondary | Incidence of ADAs | 24 months | |
| Secondary | Number of patients who achieved a complete remission (CR) or partial remission (PR) at month 12. | 12 months | |
| Secondary | Number of patients who achieved a Immunological Response (IR) at month 12. | 12 months |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05696613
GET https://conductscience.org/api/trials/v1/NCT05696613/registered